Stockreport

C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen

C4 Therapeutics, Inc.  (CCCC) 
NASDAQ:AMEX Investor Relations: ir.chinacache.com
PDF Milestone Results in $8 Million Payment to C4 Therapeutics WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical [Read more]